The dawning era of polymer therapeutics
10.1038/nrd1088
Crossref journal-article
Springer Science and Business Media LLC
Nature Reviews Drug Discovery (297)
Bibliography

Duncan, R. (2003). The dawning era of polymer therapeutics. Nature Reviews Drug Discovery, 2(5), 347–360.

Authors 1
  1. Ruth Duncan (first)
References 154 Referenced 2,828
  1. Duncan, R., Dimitrijevic, S. & Evagorou, E. G. The role of polymer conjugates in the diagnosis and treatment of cancer. S. T. P. Pharma Sciences 6, 237–263 (1996). / S. T. P. Pharma Sciences by R Duncan (1996)
  2. Donaruma, L. G. Synthetic biologically active polymers. Progr. Polym. Sci. 4, 1–25 (1974). (10.1016/0079-6700(75)90002-7) / Progr. Polym. Sci. by LG Donaruma (1974)
  3. Duncan, R. in Handbook of Anticancer Drug Development (eds Budman, D., Calvert, H. & Rowinsky, E.) (Lippincott Williams & Wilkins, Baltimore, in the press). A detailed overview describing the rationale for the design and current clinical status of polymer–anticancer-drug conjugates.
  4. Harris, J. M. & Chess, R. B. Effect of pegylation on pharmaceuticals. Nature Rev. Drug Discov. 2, 214–221 (2003). An excellent review describing PEG–protein technology and the current clinical status of PEGylated protein pharmaceuticals. An important complementary review to the one presented here. (10.1038/nrd1033) / Nature Rev. Drug Discov. by JM Harris (2003)
  5. Veronese, F. M. & Harris, J. M. (eds). Special issue: Peptide and protein PEGylation. Adv. Drug Deliv. Systems 54, 453–609 (2002). (10.1016/S0169-409X(02)00020-0) / Adv. Drug Deliv. Systems by FM Veronese (2002)
  6. Yokoyama, M. et al. Polymeric micelles as novel drug carrier: Adriamycin-conjugated poly(ethylene glycol)–poly(aspartic acid) block copolymer. J. Control Release 11, 269–278 (1990). (10.1016/0168-3659(90)90139-K) / J. Control Release by M Yokoyama (1990)
  7. Kabanov, A. V., Felgner, P. L. & Seymour, L. W. Self–assembling Complexes for Gene Delivery. From Laboratory to Clinical Trial (Wiley, Chichester, 1998). / Self–assembling Complexes for Gene Delivery. From Laboratory to Clinical Trial by AV Kabanov (1998)
  8. Fuertges, F. & Abuchowski, A. The clinical efficacy of poly(ethylene glycol)-modified proteins. J. Cont. Rel. 11, 139–148 (1990). (10.1016/0168-3659(90)90127-F) / J. Cont. Rel. by F Fuertges (1990)
  9. Jatzkewitz, H. Peptamin (glycyl-L-leucyl-mescaline) bound to blood plasma expander (polyvinylpyrrolidone) as a new depot form of a biologically active primary amine (mescaline). Z. Naturforsch. 10, 27–31 (1955). (10.1515/znb-1955-0106) / Z. Naturforsch. by H Jatzkewitz (1955)
  10. Regelson, W. & Parker, G. The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy. Cancer Invest. 4, 29–42 (1986). (10.3109/07357908609039825) / Cancer Invest. by W Regelson (1986)
  11. Ringsdorf, H. Structure and properties of pharmacologically active polymers. J. Polymer Sci. Polymer Symp. 51, 135–153 (1975). (10.1002/polc.5070510111) / J. Polymer Sci. Polymer Symp. by H Ringsdorf (1975)
  12. Gros, L., Ringsdorf, H. & Schupp, H. Polymeric antitumour agents on a molecular and on a cellular level? Angew. Chem. Int. Edn Engl. 20, 305–325 (1981). The starting point for the development of the modern concepts of polymer–drug conjugates and polymeric micelles. (10.1002/anie.198103051) / Angew. Chem. Int. Edn Engl. by L Gros (1981)
  13. Davis, F. F. The origin of pegnology. Adv. Drug Deliv. Rev. 54, 457–458 (2002). (10.1016/S0169-409X(02)00021-2) / Adv. Drug Deliv. Rev. by FF Davis (2002)
  14. Ferber, D. Gene therapy: Safer and virus-free? Science 294, 1638–1640 (2001). (10.1126/science.294.5547.1638) / Science by D Ferber (2001)
  15. Niidome, T. & Huang, L. Gene therapy progress and prospects: Nonviral vectors. Gene Ther. 9, 1647–1652 (2002). (10.1038/sj.gt.3301923) / Gene Ther. by T Niidome (2002)
  16. Gore, M. E. Gene therapy can cause leukaemia: no shock, mild horror but a probe. Gene Ther. 10, 4 (2003). Observations indicating that retroviral gene insertion is linked with leukaemia in two children previously treated with gene therapy for severe combined immunodeficiency syndrome have refuelled interest in the design of effective nonviral vectors for gene therapy. (10.1038/sj.gt.3301946) / Gene Ther. by ME Gore (2003)
  17. Brocchini, S. & Duncan, R. in Encyclopaedia of Controlled Drug Delivery (ed. Mathiowitz, E.) 786–816 (Wiley, New York, 1999). A comprehensive review describing the many polymers that have been used to synthesize polymer–drug conjugates. / Encyclopaedia of Controlled Drug Delivery by S Brocchini (1999)
  18. Rihova, B. Antibody-targeted polymer-bound drugs. Folia Microbiol. 40, 367–384 (1995). (10.1007/BF02814745) / Folia Microbiol. by B Rihova (1995)
  19. Nori, A. et al. Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells. Bioconj. Chem. 14, 44–50 (2003). (10.1021/bc0255900) / Bioconj. Chem. by A Nori (2003)
  20. Satchi, R., Connors, T. A. & Duncan, R. PDEPT: Polymer directed enzyme prodrug therapy. I. HPMA copolymer–cathepsin B and PK1 as a model combination. Brit. J. Cancer 85, 1070–1076 (2001). (10.1054/bjoc.2001.2026) / Brit. J. Cancer by R Satchi (2001)
  21. Mammen, M., Choi, S. -K. & Whitesides, G. M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn Engl. 37, 2754–2794 (1998). (10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3) / Angew. Chem. Int. Edn Engl. by M Mammen (1998)
  22. Stiriba, S. E., Krautz, H. & Frey, H. Hyperbranched molecular nanocapsules: Comparisons of the hyperbranched architecture with the perfect linear analogue. J. Am. Chem. Soc. 124, 9698–9699 (2002). (10.1021/ja026835m) / J. Am. Chem. Soc. by SE Stiriba (2002)
  23. Ferruti, P. et al. A novel modification of poly(L-lysine) leading to a soluble cationic polymer with reduced toxicity and with potential as a transfection agent. Macromol. Chem. Phys. 199, 2565–2575 (1998). (10.1002/(SICI)1521-3935(19981101)199:11<2565::AID-MACP2565>3.0.CO;2-G) / Macromol. Chem. Phys. by P Ferruti (1998)
  24. Dautzenberg, H. et al. Polycationic graft copolymers as carriers for oligonucleotide delivery. Complexes of oligonucleotides with polycationic graft copolymers. Langmuir 17, 3096–3102 (2001). (10.1021/la001779t) / Langmuir by H Dautzenberg (2001)
  25. Tomalia, D. A. et al. A new class of polymers — starburst-dendritic macromolecules. Polym. J. 17, 117–132 (1985). The start of the dendrimer chemistry revolution. (10.1295/polymj.17.117) / Polym. J. by DA Tomalia (1985)
  26. Frechet, J. M. J. Dendrimers and hyperbranched polymers: two families of three-dimensional macromolecules with similar but clearly distinct properties. J. Mater. Sci. Pure Appl. Chem. 33, 1399–1425 (1996). / J. Mater. Sci. Pure Appl. Chem. by JMJ Frechet (1996)
  27. Frechet, J. M. J. & Tomalia, D. A. Dendrimers and Other Dendritic Polymers (Wiley, Chichester, 2001). (10.1002/0470845821) / Dendrimers and Other Dendritic Polymers by JMJ Frechet (2001)
  28. Malenfant, P. R. L. & Frechet, J. M. J. in Dendrimers and Other Dendritic Polymers (eds Frechet, J. M. J. & Tomalia, D. A.) 171–196 (Wiley, Chichester, 2001). (10.1002/0470845821.ch7) / Dendrimers and Other Dendritic Polymers by PRL Malenfant (2001)
  29. Pechar, M., Ulbrich, K. & Subr, V. Poly(ethyleneglycol) multiblock copolymer as a carrier of anticancer drug doxorubicin. Bioconj. Chem. 11, 131–139 (2000). (10.1021/bc990092l) / Bioconj. Chem. by M Pechar (2000)
  30. Mirhra, M. K. & Kobayashi, S. Star and Hyperbranched Polymers (Marcel Dekker, Basel, 1999). / Star and Hyperbranched Polymers by MK Mirhra (1999)
  31. Roy, R. Recent developments in the rational design of multivalent glycoconjugates. Top. Curr. Chem. 187, 241–274 (1997). (10.1007/BFb0119259) / Top. Curr. Chem. by R Roy (1997)
  32. Chaves, F. et al. Synthesis, isolation and characterization of Plasmodium falciparum antigenic tetrabranched peptide dendrimers obtained by thiazolidine linkages. J. Pept. Res. 58, 307–316 (2001). (10.1034/j.1399-3011.2001.00921.x) / J. Pept. Res. by F Chaves (2001)
  33. Martin, C. R. & Kohli, P. The emerging field of nanotube biotechnology. Nature Rev. Drug Discov. 2, 29–37 (2003). (10.1038/nrd988) / Nature Rev. Drug Discov. by CR Martin (2003)
  34. Painter, P. C. & Coleman, M. C. Fundamentals of Polymer Science 2nd edn (CRC, Boca Raton, 1997). / Fundamentals of Polymer Science by PC Painter (1997)
  35. Cavagnaro, J. A. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nature Rev. Drug Discov. 1, 469–476 (2002). (10.1038/nrd822) / Nature Rev. Drug Discov. by JA Cavagnaro (2002)
  36. Seymour, L. W. Synthetic polymers with intrinsic anticancer activity. J. Bioact. Comp. Polymers 6, 178–216 (1991). (10.1177/088391159100600205) / J. Bioact. Comp. Polymers by LW Seymour (1991)
  37. Breslow, D. S. Biologically active synthetic polymers. Pure Appl. Chem. 46, 103–113 (1976). (10.1351/pac197646020103) / Pure Appl. Chem. by DS Breslow (1976)
  38. Regelson, W. Advances in intraperitoneal (intracavitary) administration of synthetic polymers for immunotherapy and chemotherapy. J. Bioact. Comp. Polymers 1, 84–106 (1986). (10.1177/088391158600100109) / J. Bioact. Comp. Polymers by W Regelson (1986)
  39. Mistry, C. D. & Gokal, R. Icodextrin in peritoneal dialysis: Early development and clinical use. Perit. Dial. Int. 14 (Suppl. 2), 13–21 (1994). (10.1177/089686089401402S02) / Perit. Dial. Int. by CD Mistry (1994)
  40. Jarvan, C. M. et al. Anti-HIV type 1 activity of sulfated derivatives of dextrin against primary viral isolates of HIV type 1 in lymphocytes and monocyte-derived macrophages. AIDS Res. Hum. Retroviruses 13, 875–880 (1997). (10.1089/aid.1997.13.875) / AIDS Res. Hum. Retroviruses by CM Jarvan (1997)
  41. Shaunak, S. et al. Reduction of the viral load of HIV-1 after the intraperitoneal administration of dextrin-2-sulphate in patients with AIDS. AIDS 12, 399–409 (1998). Dextrin-2–sulphate was the first sulphated polysaccharide to be administered clinically via the peritoneal route. (10.1097/00002030-199804000-00009) / AIDS by S Shaunak (1998)
  42. Thornton, M. et al. Anti-Kaposi's sarcoma and angiogenic activities of sulfated dextrins. Antimicrob. Agents Chemother. 43, 2528–2533 (1999). (10.1128/AAC.43.10.2528) / Antimicrob. Agents Chemother. by M Thornton (1999)
  43. Stafford, M. K. et al. A placebo-controlled, double-blind prospective study in healthy female volunteers of dextrin sulphate gel: novel potential intravaginal virucide. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14, 213–218 (1997). (10.1097/00042560-199703010-00003) / J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. by MK Stafford (1997)
  44. Teitlebaum, M. S. D., Arnon, R. & Sela, M. Copaxone in experimental allergic encephalomyelitis and animal model for CMLS. Cell Biol. Life Sci. 53, 24–28 (1997). (10.1007/PL00000576) / Cell Biol. Life Sci. by MSD Teitlebaum (1997)
  45. Johnson, K. P. et al. Copaxone disease progression. Neurology 45, 1268–1276 (1995). (10.1212/WNL.45.7.1268) / Neurology by KP Johnson (1995)
  46. Slatopolsky, E. A. et al. RenaGel®, a nonabsorbed calcium- and phosphate-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int. 55, 299–307 (1999). (10.1046/j.1523-1755.1999.00240.x) / Kidney Int. by EA Slatopolsky (1999)
  47. Mandeville, W. H. & Goldberg, D. I. The sequestration of bile acids, a non-absorbed method for cholersterol reduction. A review. Curr. Pharm. Des. 3, 15–28 (1997). (10.2174/138161280301221005123941) / Curr. Pharm. Des. by WH Mandeville (1997)
  48. Gregoriadis, G. et al. Polysialic acids: potential in drug delivery. FEBS Lett. 315, 271–276 (1993). (10.1016/0014-5793(93)81177-2) / FEBS Lett. by G Gregoriadis (1993)
  49. Roy, R. et al. Synthesis and antigenic properties of sialic acid-base dendrimers. ACS Symp. Ser. 560, 104–119 (1994). (10.1021/bk-1994-0560.ch007) / ACS Symp. Ser. by R Roy (1994)
  50. Sigal, G. B. et al. Polyacrylamides bearing pendant α-sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus: The strong inhibition reflects enhanced binding through cooperative polyvalent interactions. J. Am. Chem. Soc. 118, 3789–3800 (1996). (10.1021/ja953729u) / J. Am. Chem. Soc. by GB Sigal (1996)
  51. Rihova, B. & Riha, I. Immunological problems of polymer-bound drugs. Crit. Rev. Ther. Drug Carrier Syst. 1, 311–374 (1985). / Crit. Rev. Ther. Drug Carrier Syst. by B Rihova (1985)
  52. Rihova, B. Biocompatibility of biomaterials: Haemocompatibility, immunocompatibility and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers. Adv. Drug Deliv. Rev. 21, 157–176 (1996). An excellent review addressing the issues relating to the safety of polymeric materials and water soluble polymers used as drug carriers. (10.1016/S0169-409X(96)00404-8) / Adv. Drug Deliv. Rev. by B Rihova (1996)
  53. Seymour, L. W. et al. Effect of molecular weight (Mω) of N-(2-hydroxypropyl) methacrylamide copolymers on body distributions and rate of excretion after subcutaneous, intraperitoneal and intravenous administration to rats. J. Biomed. Mat. Res. 21, 1341–1358 (1987). (10.1002/jbm.820211106) / J. Biomed. Mat. Res. by LW Seymour (1987)
  54. Kobayashi, H. et al. Micro-MR angiography of normal and intratumoural vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimer-based MR contrast agents. J. Magn. Reson. Imaging 14, 705–713 (2001). (10.1002/jmri.10025) / J. Magn. Reson. Imaging by H Kobayashi (2001)
  55. Robinson, B. V. et al. PVP: A Critical Review of the Kinetics and Toxicology of Polyvinylpyrrolidone (Povidone). (Lewis, Chelsea, 1990). / PVP: A Critical Review of the Kinetics and Toxicology of Polyvinylpyrrolidone (Povidone) by BV Robinson (1990)
  56. Seymour, L. W. et al. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer 31, 766–770 (1995). (10.1016/0959-8049(94)00514-6) / Eur. J. Cancer by LW Seymour (1995)
  57. Volfova, I. et al. Biocompatibility of biopolymers. J. Bioact. Biocompat. Polymers 7, 175–190 (1992). (10.1177/088391159200700205) / J. Bioact. Biocompat. Polymers by I Volfova (1992)
  58. Rihova, B. Immunogenicity of N-(2-hydroxypropyl) methacrylamide copolymers. Makromol. Chem. 9, 13–24. (10.1002/macp.1985.020091985103)
  59. Rihova, B. et al. Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect of haematopoietic stem cells in bone marrow in vivo and effect on mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 10, 335–342 (1989). (10.1016/0142-9612(89)90075-6) / Biomaterials by B Rihova (1989)
  60. Yeung, T. K. et al. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl) methacrylamide conjugates: an experimental study in the rat. Cancer Chemother. Pharmacol. 29, 105–111 (1991). (10.1007/BF00687318) / Cancer Chemother. Pharmacol. by TK Yeung (1991)
  61. Duncan, R., Coatsworth, J. K. & Burtles, S. Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer–doxorubicin (PK1). Hum. Exp. Toxicol. 17, 93–104 (1998). The first paper describing a good laboratory practice (GLP) preclinical toxicological study of a polymer–drug conjugate. / Hum. Exp. Toxicol. by R Duncan (1998)
  62. Nagle, T. et al. The further evolution of biotech. Nature Rev. Drug Discov. 2, 75–79 (2003). (10.1038/nrd989) / Nature Rev. Drug Discov. by T Nagle (2003)
  63. Brekke, O. H. & Sandlie, I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nature Rev. Drug Discov. 2, 52–62 (2003). (10.1038/nrd984) / Nature Rev. Drug Discov. by OH Brekke (2003)
  64. Nucci, M. L., Shorr, D. & Abuchowski, A. The therapeutic values of poly(ethylene glycol)-modified proteins. Adv. Drug Deliv. Rev. 6, 133–151 (1991). (10.1016/0169-409X(91)90037-D) / Adv. Drug Deliv. Rev. by ML Nucci (1991)
  65. Delgado, C., Francis, G. E. & Fisher, D. The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. 9, 249–304 (1992). / Crit. Rev. Ther. Drug Carrier Syst. by C Delgado (1992)
  66. Monfardini, C. & Veronese, F. M. Stabilisation of substances in the circulation. Bioconj. Chem. 9, 418–450 (1998). (10.1021/bc970184f) / Bioconj. Chem. by C Monfardini (1998)
  67. Francis, G. et al. Polyethylene glycol modification: Relevance to improved methodology to tumour targeting. J. Drug Target. 3, 321–340 (1996). (10.3109/10611869608996824) / J. Drug Target. by G Francis (1996)
  68. Roberts, M. J., Bentley, M. D. & Harris, J. M. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54, 459–476 (2002). (10.1016/S0169-409X(02)00022-4) / Adv. Drug Deliv. Rev. by MJ Roberts (2002)
  69. Goodson, R. J. & Katre, N. V. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology 8, 343–346 (1990). / Biotechnology by RJ Goodson (1990)
  70. Chapman, A. P. et al. Therapeutic antibody fragments with prolonged in vivo half-lives. Nature Biotechnol. 17, 780–783 (1999). (10.1038/11717) / Nature Biotechnol. by AP Chapman (1999)
  71. Sato, H. Enzymatic procedure for site-specific pegylation of proteins. Adv. Drug Deliv. Rev. 54, 487–504 (2002). (10.1016/S0169-409X(02)00024-8) / Adv. Drug Deliv. Rev. by H Sato (2002)
  72. Bailon, P. & Berthold, W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm. Sci. Technol. Today 1, 352–356 (1998). (10.1016/S1461-5347(98)00086-8) / Pharm. Sci. Technol. Today by P Bailon (1998)
  73. Lee, S et al. Drug delivery systems employing 1,6-elimination: Releasable poly(ethylene glycol) conjugates of proteins. Bioconj. Chem. 12, 163–169 (2001). (10.1021/bc000064z) / Bioconj. Chem. by S Lee (2001)
  74. Levy, Y. et al. Adenosine deaminase deficiency with late onset or recurrent infections: response to treatment with polyethylene glycol modified adenosine deaminase. J. Pediatr. 113, 312–317 (1988). (10.1016/S0022-3476(88)80271-3) / J. Pediatr. by Y Levy (1988)
  75. Graham, M. L. PEGASPARAGINASE: a review of clinical studies. Adv. Drug Deliv. Rev. (in the press).
  76. Kinstler, O. et al. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 54, 477–485 (2002). (10.1016/S0169-409X(02)00023-6) / Adv. Drug Deliv. Rev. by O Kinstler (2002)
  77. Reddy, K. R., Modi, M. W. & Pedder, S. Use of peginterferon α-2a (40KD) (Pegasys®) for the treatment of hepatitis C. Adv. Drug Deliv. Rev. 54, 571–586 (2002). (10.1016/S0169-409X(02)00028-5) / Adv. Drug Deliv. Rev. by KR Reddy (2002)
  78. Wang, Y. -S. et al. Structural and biological characterisation of pegylated recombinant interferon α-2b and its therapeutic implications. Adv. Drug Deliv. Rev. 54, 547–570 (2002). (10.1016/S0169-409X(02)00027-3) / Adv. Drug Deliv. Rev. by Y-S Wang (2002)
  79. Bukowski, R. et al. Pegylated interferon α-2b treatment for patients with solid tumors: a phase I/II study. J. Clin. Oncol. 20, 3841–3849 (2002). (10.1200/JCO.2002.02.051) / J. Clin. Oncol. by R Bukowski (2002)
  80. De Duve, C. et al. Lysosomotropic agents. Biochem. Pharmacol. 23, 2495–2531 (1974). (10.1016/0006-2952(74)90174-9) / Biochem. Pharmacol. by C De Duve (1974)
  81. Huang, P. S. & Oliff, A. Drug-targeting strategies in cancer therapy. Curr. Opin. Genet. Dev. 11, 104–110 (2001). (10.1016/S0959-437X(00)00164-7) / Curr. Opin. Genet. Dev. by PS Huang (2001)
  82. Duncan, R. & Spreafico, F. Polymer conjugates: Pharmacokinetic considerations for design and development. Clin. Pharmacokinet. 27, 290–306 (1994). (10.2165/00003088-199427040-00004) / Clin. Pharmacokinet. by R Duncan (1994)
  83. Matsumura, Y. & Maeda, H. A new concept for macromolecular therapies in cancer chemotherapy: mechanism of tumouritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res. 6, 6387–6392 (1986). / Cancer Res. by Y Matsumura (1986)
  84. Seymour, L. W. et al. Tumouritropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Brit. J. Cancer 70, 636–641 (1994). (10.1038/bjc.1994.363) / Brit. J. Cancer by LW Seymour (1994)
  85. Gianasi, E. et al. HPMA copolymer platinates as novel antitumor agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur. J. Cancer 35, 994–1002 (1999). (10.1016/S0959-8049(99)00030-1) / Eur. J. Cancer by E Gianasi (1999)
  86. Rejmanova, P. et al. Stability in plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers. Biomaterials 6, 45–48 (1985). (10.1016/0142-9612(85)90037-7) / Biomaterials by P Rejmanova (1985)
  87. Duncan, R. et al. Polymers containing enzymatically degradable bonds. 7. Design of oligopeptide side chains in poly[N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Makromol. Chem. 184, 1997–2008 (1984). (10.1002/macp.1983.021841005) / Makromol. Chem. by R Duncan (1984)
  88. Etrych, T. et al. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J. Control Release 73, 89–102 (2001). (10.1016/S0168-3659(01)00281-4) / J. Control Release by T Etrych (2001)
  89. Kopecek, J. & Bazilova, H. Poly[N-(hydroxypropyl) methacrylamide]. I. Radical polymerisation and copolymerisation. Eur. Polymer J. 9, 7–14 (1973). (10.1016/0014-3057(73)90063-3) / Eur. Polymer J. by J Kopecek (1973)
  90. Sprincl, L. et al. New types of synthetic infusion solutions. III. Elimination and retention of poly[N-(2-hydroxypropyl) methacrylamide] in a test organism. J. Biomed. Mater. Res. 10, 953–963 (1976). (10.1002/jbm.820100612) / J. Biomed. Mater. Res. by L Sprincl (1976)
  91. Duncan, R. & Kopecek, J. Soluble synthetic polymers as potential drug carriers. Adv. Polymer Sci. 57, 51–101 (1984). (10.1007/3-540-12796-8_10) / Adv. Polymer Sci. by R Duncan (1984)
  92. Duncan, R. Drug–polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 3, 175–210 (1992). (10.1097/00001813-199206000-00001) / Anticancer Drugs by R Duncan (1992)
  93. Duncan, R. et al. Preclinical evaluation of polymer-bound doxorubicin. J. Control Release 19, 331–346 (1992). An important paper describing the preclinical and in vivo antitumour studies that paved the way for HPMA copolymer–doxorubicin to enter clinical testing. (10.1016/0168-3659(92)90088-9) / J. Control Release by R Duncan (1992)
  94. Kopecek, J. et al. HPMA copolymer–anticancer drug conjugates: design, activity and mechanism of action. Eur. J. Pharm. Biopharm. 50, 61–81 (2000). (10.1016/S0939-6411(00)00075-8) / Eur. J. Pharm. Biopharm. by J Kopecek (2000)
  95. Vasey, P. et al. Phase I clinical and pharmacokinetic study of PKI (N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin): first member of a new class of chemotherapeutic agents — drug–polymer conjugates. Clin. Cancer Res. 5, 83–94 (1999). The first Phase I clinical trial evaluating a synthetic polymer–drug conjugate as an anticancer agent. / Clin. Cancer Res. by P Vasey (1999)
  96. Seymour, L. W. et al. Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20, 1668–1676 (2002). The first clinical study describing a synthetic biomimetic polymer conjugate. HPMA copolymer–doxorubicin containing additional galactose residues was designed to target the hepatocyte asialoglycoprotein receptor. (10.1200/JCO.2002.20.6.1668) / J. Clin. Oncol. by LW Seymour (2002)
  97. Thomson, A. H. et al. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. Brit. J. Cancer 81, 99–107 (1999). (10.1038/sj.bjc.6690657) / Brit. J. Cancer by AH Thomson (1999)
  98. Duncan, R. et al. Fate of N-(2-hydroxypropyl) methacrylamide copolymers with pendant galactosamine residues after intravenous administration to rats. Biochim. Biophys. Acta 880, 62–71 (1986). (10.1016/0304-4165(86)90120-0) / Biochim. Biophys. Acta by R Duncan (1986)
  99. Ashwell, G. & Harford, J. Carbohydrate recognition systems of the liver. Ann. Rev. Biochem. 51, 531–554 (1982). (10.1146/annurev.bi.51.070182.002531) / Ann. Rev. Biochem. by G Ashwell (1982)
  100. Julyan, P. J. et al. Preliminary clinical study of the distribution of HPMA copolymer–doxorubicin bearing galactosamine. J. Control Release 57, 281–290 (1999). (10.1016/S0168-3659(98)00124-2) / J. Control Release by PJ Julyan (1999)
  101. Meerum Terwogt, J. M. et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 12, 315–323 (2001). (10.1097/00001813-200104000-00003) / Anticancer Drugs by JM Meerum Terwogt (2001)
  102. Schoemaker, N. E. et al. A phase I and pharmacokinetic study of MAG-CPT, a water soluble polymer conjugate of camptothecin. Brit. J. Cancer 87, 608–614 (2002). (10.1038/sj.bjc.6600516) / Brit. J. Cancer by NE Schoemaker (2002)
  103. Li, C. et al. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)–paclitaxel conjugate. Cancer Res. 58, 2404–2409 (1998). An important study describing preclinical properties of PGA–paclitaxel. / Cancer Res. by C Li (1998)
  104. Sludden, A. V. et al. Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)–paclitaxel conjugate. Proc. Am. Assoc. Cancer Res. 42, 2883 (2001). / Proc. Am. Assoc. Cancer Res. by AV Sludden (2001)
  105. Sabbatini, P. et al. A phase I/II study of PG–paclitaxel (CT-2103) in patients (pts) with recurrent ovarian, fallopian tube, or peritoneal cancer. Proc. Am. Soc. Clin. Oncol. 871 (2002).
  106. Kudelka, A. P. et al. Preliminary report of a phase I study of escalating dose PG–paclitaxel (CT-2103) and fixed dose cisplatin in patients with solid tumors Proc. Am. Soc. Clin. Oncol. 2146 (2002).
  107. Schulz, J. et al. Phase II study of CT-2103 in patients with colorectal cancer having recurrent disease after treatment with a 5-fluorouracil-containing regimen. Proc. Am. Soc. Clin. Oncol. 2330 (2002).
  108. Shaffer, S. A. et al. Metabolism of poly-L-glutamic acid (PG)–paclitaxel (CT-2103); proteolysis by lysosomal cathepsin B and identification of intermediate metabolites. Proc. Am. Assoc. Cancer Res. 43, 2067 (2002). / Proc. Am. Assoc. Cancer Res. by SA Shaffer (2002)
  109. Denis, L. et al. A Phase I study of PEG–camptothecin (PEG–CPT) in patients with advanced solid tumours: A novel formulation for an insoluble but active agent. Proc. Am. Soc. Clin. Oncol. 19, 700 (2000). / Proc. Am. Soc. Clin. Oncol. by L Denis (2000)
  110. Greenwald, R. B. et al. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55, 217–250 (2003). (10.1016/S0169-409X(02)00180-1) / Adv. Drug Deliv. Rev. by RB Greenwald (2003)
  111. Rice, J. R., Stewart, D. R. & Nowotnik, D. P. Enhanced antitumour activity of a new polymer linked DACH–platinum complex. Proc. Am. Assoc. Cancer Res. 43, 307 (2002). / Proc. Am. Assoc. Cancer Res. by JR Rice (2002)
  112. Gianasi, E. et al. HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation. J. Drug Targeting 10, 549–556 (2002). (10.1080/1061186021000072456) / J. Drug Targeting by E Gianasi (2002)
  113. Ochi, Y. et al. DE-310, a novel macromolecular carrier for the camptothecin analogue DX-8951f[II]: Its antitumour activities in several model systems of human and murine tumours. Proc. Am. Assoc. Cancer Res. 42, 748 (2001). / Proc. Am. Assoc. Cancer Res. by Y Ochi (2001)
  114. De Vries, P. et al. Optimisation of CT2106: a water soluble poly-L-glutamic acid (PG)–camptothecin conjugate with enhanced in vivo antitumor efficacy. Proc. AACR-NCI-EORTC Int. Conf. 100 (2001).
  115. Batrakova, E. V. et al. Anthracycline antibiotics non-covalently incorporated into block copolymer micelles: in vivo evaluation of anticancer activity. Br. J. Cancer 74, 1545–1552 (1996). (10.1038/bjc.1996.587) / Br. J. Cancer by EV Batrakova (1996)
  116. Alakhov, V. et al. Block copolymer-based formulations of doxorubicin. From cell screen to clinical trials. Colloids Surf. B: Biointerfaces 16, 113–134 (1999). The first micelle-based formulation of doxorubicin, and its transfer to the clinic. (10.1016/S0927-7765(99)00064-8) / Colloids Surf. B: Biointerfaces by V Alakhov (1999)
  117. Kataoka, K. et al. Block copolymer micelles as vehicles for drug delivery. J. Control Release 24, 119–132 (1993). (10.1016/0168-3659(93)90172-2) / J. Control Release by K Kataoka (1993)
  118. Nakanishi, T. et al. Development of the polymer micelle carrier system for doxorubicin. J. Control Release 74, 295–302 (2001). A description of the preclinical development of the first micelle-based doxorubicin formulation containing covalently bound drug. (10.1016/S0168-3659(01)00341-8) / J. Control Release by T Nakanishi (2001)
  119. Sat, Y. N. et al. Comparison of vascular permeability and enzymatic activation of the polymeric prodrug HPMA copolymer–doxorubicin (PK1) in human tumour xenografts. Proc. Am. Assoc. Cancer Res. 90, 41 (1999). / Proc. Am. Assoc. Cancer Res. by YN Sat (1999)
  120. Jain, R. K. Delivery of molecular and cellular medicine to solid tumours. Adv. Drug Deliv. Rev. 46, 149–168 (2001). (10.1016/S0169-409X(00)00131-9) / Adv. Drug Deliv. Rev. by RK Jain (2001)
  121. Wu, J., Akaike, T. & Maeda, H. Modulation of enhanced vascular permeability in tumours by a bradykinin antagonist, a cyclooxygenase inhibitor. Cancer Res. 58, 159–165 (1998). / Cancer Res. by J Wu (1998)
  122. Li, C. et al. Tumour irradiation enhances the tumour-specific distribution of poly(L-glutamic acid)–conjugated paclitaxel and its antitumour efficacy. Clin. Cancer Res. 6, 2829–2834 (2000). / Clin. Cancer Res. by C Li (2000)
  123. Boussif, O. et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc. Natl Acad. Sci. USA 92, 7297–7301 (1995). (10.1073/pnas.92.16.7297) / Proc. Natl Acad. Sci. USA by O Boussif (1995)
  124. Remy, J. -S. et al. Gene transfer with lipospermines and polyethylenimines. Adv. Drug Deliv. Rev. 30, 85–95 (1998). (10.1016/S0169-409X(97)00109-9) / Adv. Drug Deliv. Rev. by J-S Remy (1998)
  125. Merdan, T. et al. Intracellular processing of poly(ethyleneimine)/ribozyme complexes can be observed in living cells by using confocal laser scanning microscopy and inhibitor experiments. Pharm. Res. 19, 140–146 (2002). (10.1023/A:1014212630566) / Pharm. Res. by T Merdan (2002)
  126. Brunner, S. et al. Overcoming the nuclear barrier: cell cycle independent nonviral gene transfer with linear polyethylenimine or electroporation. Mol. Ther. 5, 80–86 (2002). (10.1006/mthe.2001.0509) / Mol. Ther. by S Brunner (2002)
  127. Wightman, L. et al. Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. J. Gene Med. 3, 362–372 (2001). (10.1002/jgm.187) / J. Gene Med. by L Wightman (2001)
  128. Kircheis, R. et al. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther. 8, 28–40 (2001). (10.1038/sj.gt.3301351) / Gene Ther. by R Kircheis (2001)
  129. Lisziewicz, J. et al. Induction of potent human immunodeficiency virus type 1-specific T cell-restricted immunity by genetically modified dendritic cells. J. Virol. 75, 7621–7628 (2001). (10.1128/JVI.75.16.7621-7628.2001) / J. Virol. by J Lisziewicz (2001)
  130. Vernejoul, F. Antitumor effect of in vivo somatostatin receptor sst2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res. 62, 6124–6131 (2002). / Cancer Res. by F Vernejoul (2002)
  131. Ferruti, P., Marchisio, M. A. & Duncan, R. Poly(amido-amine)s: Biomedical applications Macromol. Rapid Comm. 23, 332–355 (2002). (10.1002/1521-3927(20020401)23:5/6<332::AID-MARC332>3.0.CO;2-I) / Macromol. Rapid Comm. by P Ferruti (2002)
  132. Stayton, P. S. et al. Molecular engineering of proteins and polymers for targeting and intracellular delivery of therapeutics. J. Control Release 65, 203–220 (2000). (10.1016/S0168-3659(99)00236-9) / J. Control Release by PS Stayton (2000)
  133. Putnam, D. et al. Polymer-based gene delivery with low cytotoxicity by a unique balance of side chain termini. Proc. Natl Acad Sci. USA 98, 1200–1205 (2001). (10.1073/pnas.98.3.1200) / Proc. Natl Acad Sci. USA by D Putnam (2001)
  134. Satchi-Fainaro, R. et al. PDEPT: Polymer directed enzyme prodrug therapy. II. HPMA copolymer-β-lactamase and HPMA-C-Dox as a model combination. Bioconj. Chem. (in the press). (10.1021/bc020091k)
  135. Duncan, R. et al. Polymer–drug conjugates, PDEPT and PELT: Basic principles for design and transfer from the laboratory to the clinic. J. Control Release 74, 135–146 (2001). (10.1016/S0168-3659(01)00328-5) / J. Control Release by R Duncan (2001)
  136. Gopin, A. et al. A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger. Angew. Chem. Int. Edn Engl. 42, 327–332 (2003). (10.1002/anie.200390108) / Angew. Chem. Int. Edn Engl. by A Gopin (2003)
  137. Kerbel, R. & Folkman, J. Clinical translation of angiogenic inhibitors. Nature Rev. Cancer 2, 727–739 (2002). (10.1038/nrc905) / Nature Rev. Cancer by R Kerbel (2002)
  138. Satchi-Fainaro, R. et al. Polymer therapeutics of angiogenesis inhibitors: HPMA copolymer–TNP-470 conjugate. Proc. Intl Symp. Controlled Rel. Bioact. Mater. 29, 209–210 (2002). An excellent paper describing in vitro and in vivo activity of the first polymer anti-angiogenic conjugate. / Proc. Intl Symp. Controlled Rel. Bioact. Mater. by R Satchi-Fainaro (2002)
  139. Tomlinson, R. et al. Pendent chain functionalised polyacetals that display pH-dependent degradation: A platform for the development of novel polymer therapeutics. Macromolecules 35, 473–480 (2002). (10.1021/ma0108867) / Macromolecules by R Tomlinson (2002)
  140. Gillies, E. R. & Frechet, J. M. J. Designing macromolecules for therapeutic applications: Polyester dendrimer–poly(ethylene oxide) 'bow-tie' hybrids with tunable molecular weight and architecture. J. Am. Chem. Soc. 124, 14137–14146 (2002). (10.1021/ja028100n) / J. Am. Chem. Soc. by ER Gillies (2002)
  141. Cloninger, M. J. Biological applications of dendrimers. Curr. Opin. Chem. Biol. 6, 742–748 (2002). (10.1016/S1367-5931(02)00400-3) / Curr. Opin. Chem. Biol. by MJ Cloninger (2002)
  142. Wiwattanapatapee, R. et al. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: A potential oral delivery system. Pharm. Res. 17, 991–998 (2000). (10.1023/A:1007587523543) / Pharm. Res. by R Wiwattanapatapee (2000)
  143. Lendlein, A. & Langer, R. Biodegradable, elastic, shape-memory polymers for potential biomedical applications. Science 296, 1673–1676 (2002). (10.1126/science.1066102) / Science by A Lendlein (2002)
  144. Chanda, S. K. & Caldwell, J. S. Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov. Today 8, 168–174 (2003). (10.1016/S1359-6446(02)02595-3) / Drug Discov. Today by SK Chanda (2003)
  145. Atkins, J. H. & Gershell, L. J. Selective anticancer drugs. Nature Rev. Cancer 1, 645–646 (2002). (10.1038/nrc900) / Nature Rev. Cancer by JH Atkins (2002)
  146. The Journal of Gene Medicine, www.wiley.co.uk.genmed (2002).
  147. Jain, R. K. The next frontier of molecular medicine: Delivery of therapeutics. Nature Med. 4, 655–657 (1998). (10.1038/nm0698-655) / Nature Med. by RK Jain (1998)
  148. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nature Rev. Drug Discov. 2, 750–763 (2002). An excellent review describing ligands and technologies that have been explored for tumour targeting. Includes information on antibodies, immunoliposomes, immunotoxins and immuno–polymer conjugates. (10.1038/nrc903) / Nature Rev. Drug Discov. by TM Allen (2002)
  149. Langer, R. Drug delivery and targeting. Nature 392, 5–10 (1998). / Nature by R Langer (1998)
  150. Iwai, K., Maeda, H. & Konno, T. Use of oily contrast medium for selective drug targeting to tumour: Enhanced therapeutic effect and X-ray image. Cancer Res. 44, 2114–2121 (1984). / Cancer Res. by K Iwai (1984)
  151. Konno, T. & Maeda, H. in Neoplsma of the Liver (eds Okada, K. & Ishak, K. G.) 343–352 (Springer, New York, 1987). (10.1007/978-4-431-68349-0_27) / Neoplsma of the Liver by T Konno (1987)
  152. Maeda, H. & Konno, T. in Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug (eds Maeda, H., Edo, K. & Ishida, N.) 227–267 (Springer, Berlin, 1997). (10.1007/978-4-431-66914-2_12) / Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug by H Maeda (1997)
  153. Jain, R. K. Delivery of molecular and cellular medicines to solid tumours. Adv. Drug Deliv. Rev. 26, 71–90 (1997). (10.1016/S0169-409X(97)00027-6) / Adv. Drug Deliv. Rev. by RK Jain (1997)
  154. Mukherjee, A. et al. How to optimise pegvisomant treatment of acromegaly safely? Endocrine Abstracts 4, OC8 (2002). / Endocrine Abstracts by A Mukherjee (2002)
Dates
Type When
Created 22 years, 3 months ago (May 15, 2003, 1:19 p.m.)
Deposited 1 year, 7 months ago (Jan. 9, 2024, 4:40 p.m.)
Indexed 5 days, 2 hours ago (Aug. 19, 2025, 6:42 a.m.)
Issued 22 years, 3 months ago (May 1, 2003)
Published 22 years, 3 months ago (May 1, 2003)
Published Print 22 years, 3 months ago (May 1, 2003)
Funders 0

None

@article{Duncan_2003, title={The dawning era of polymer therapeutics}, volume={2}, ISSN={1474-1784}, url={http://dx.doi.org/10.1038/nrd1088}, DOI={10.1038/nrd1088}, number={5}, journal={Nature Reviews Drug Discovery}, publisher={Springer Science and Business Media LLC}, author={Duncan, Ruth}, year={2003}, month=may, pages={347–360} }